B-type proto-oncogene-mutated tumors of colon cancer: promising therapeutic approaches.

Abstract excerpt

PURPOSE OF REVIEW: B-type proto-oncogene (BRAF) mutations have been observed in about 10.8% of patients with colorectal cancer (CRC). These patients do not respond to standard therapy with anti-epidermal growth factor receptor kinase (EGFR). Here we review novel BRAF inhibitors that are currently being investigated in these tumors. RECENT FINDINGS: Clinical experience with the BRAF inhibitor vemurafenib in CRC...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antibodies, Monoclonal, Humanized
• Share to Antineoplastic Combined Chemotherapy Protocols